Format
Sort by
Items per page

Send to

Choose Destination

Best matches for cannabidiol and huntington's disease:

Controlled clinical trial of cannabidiol in Huntington's disease. Consroe P et al. Pharmacol Biochem Behav. (1991)

Neurological Aspects of Medical Use of Cannabidiol. Mannucci C et al. CNS Neurol Disord Drug Targets. (2017)

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. López-Sendón Moreno JL et al. J Neurol. (2016)

Search results

Items: 1 to 20 of 25

1.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
2.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2018 Aug 23. doi: 10.5740/jaoacint.18-0208. [Epub ahead of print]

PMID:
30139415
3.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

4.

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Peres FF, Lima AC, Hallak JEC, Crippa JA, Silva RH, Abílio VC.

Front Pharmacol. 2018 May 11;9:482. doi: 10.3389/fphar.2018.00482. eCollection 2018. Review.

5.

Neurological Aspects of Medical Use of Cannabidiol.

Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G.

CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi: 10.2174/1871527316666170413114210. Review.

PMID:
28412918
6.

Torsional stress promotes trinucleotidic expansion in spermatids.

Simard O, Niavarani SR, Gaudreault V, Boissonneault G.

Mutat Res. 2017 Aug;800-802:1-7. doi: 10.1016/j.mrfmmm.2017.04.001. Epub 2017 Apr 9.

PMID:
28412438
7.

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.

Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz J.

Int J Mol Sci. 2017 Mar 23;18(4). pii: E684. doi: 10.3390/ijms18040684.

8.

Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?

Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D.

Expert Rev Clin Pharmacol. 2017 Apr;10(4):443-455. doi: 10.1080/17512433.2017.1292849. Epub 2017 Feb 28. Review.

PMID:
28276775
9.
10.

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J.

J Neurol. 2016 Jul;263(7):1390-400. doi: 10.1007/s00415-016-8145-9. Epub 2016 May 9.

PMID:
27159993
11.

Endocannabinoid System: A Multi-Facet Therapeutic Target.

Kaur R, Ambwani SR, Singh S.

Curr Clin Pharmacol. 2016;11(2):110-7. Review.

PMID:
27086601
12.

Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM.

Mol Pharmacol. 2016 Mar;89(3):364-75. doi: 10.1124/mol.115.101980. Epub 2015 Dec 23. Erratum in: Mol Pharmacol. 2016 Jun;89(6):694.

PMID:
26700564
13.

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.

ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9.

14.

Is the cardiovascular system a therapeutic target for cannabidiol?

Stanley CP, Hind WH, O'Sullivan SE.

Br J Clin Pharmacol. 2013 Feb;75(2):313-22. doi: 10.1111/j.1365-2125.2012.04351.x. Review.

15.

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.

Br J Clin Pharmacol. 2013 Feb;75(2):323-33. doi: 10.1111/j.1365-2125.2012.04341.x. Review.

16.

Cannabinoids: novel medicines for the treatment of Huntington's disease.

Sagredo O, Pazos MR, Valdeolivas S, Fernandez-Ruiz J.

Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):41-8. Review.

PMID:
22280340
17.

Cannabidiol in humans-the quest for therapeutic targets.

Zhornitsky S, Potvin S.

Pharmaceuticals (Basel). 2012 May 21;5(5):529-52. doi: 10.3390/ph5050529.

18.

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.

J Neurosci Res. 2011 Sep;89(9):1509-18. doi: 10.1002/jnr.22682. Epub 2011 Jun 14.

PMID:
21674569
19.

Prospects for cannabinoid therapies in basal ganglia disorders.

Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.

Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x. Review.

20.

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.

Walther S, Halpern M.

Pharmaceuticals (Basel). 2010 Aug 17;3(8):2689-2708. Review.

Supplemental Content

Loading ...
Support Center